Author

Dirk Lindner 1

1 Takeda,Zurich,Switzerland

DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS

Stefan Schreiber, Silvio Danese, Laurent Peyrin-Biroulet, Jean-Frederic Colombel, Bruce E. Sands, Dirk Lindner, Richard A. Lirio, Christian Agboton, Edward V. Loftus Jr.

EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMAB FOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OF THE PHASE 4 EARNEST TRIAL

Simon Travis, Mark S. Silverberg, Silvio Danese, Paolo Gionchetti, Mark Lowenberg, Dirk Lindner, Armella Escher, Stephen Jones, Bo Shen

REAL-WORLD EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A POOLED MULTICENTRE OBSERVATIONAL COHORT ANALYSIS OF CLINICAL AND MODELED PHARMACOLOGICAL DATA

Niels Vande Casteele, William Sandborn, Brian G. Feagan, Severine Vermeire, Parambir Dulai, Julian Panés, Andres Yarur, Xavier Roblin, Shomron Ben-Horin, Iris Dotan, Mark Osterman, Dirk Lindner, Christian Agboton, Maria Rosario, Teresa Osborn

Item 1 - 3 / 3
1